Resources and insights

Albuquerque, New Mexico, USA June 20, 2025 EquiSeq, a leader in developing genetic tests for horses, is pleased to announce the appointment of Madison R. Sanders to its Board of Directors, effective immediately. Ms. Sanders is an experienced equestrian with a proven track record in sales and marketing. She is a lifelong hunter/jumper equestrian and a driven entrepreneur. She left the corporate world, where she worked in sales and marketing, to found Elite Equine Marketplace, a digital platform tailored to the hunter/jumper community. “We are thrilled to welcome Ms. Sanders to our Board,” said CEO and Chief Scientific Officer Paul Szauter. “Madi combines decades of experience as an equestrian with a record of success in sales and marketing. In her new role, Ms. Sanders will increase the adoption of EquiSeq’s DNA test among horse owners, breeders, and veterinarians.” “I am honored to join EquiSeq at this time of opportunity,” said Ms. Sanders. “I look forward to working with the Board to achieve its goal of improving horse health through genetic testing and breeding programs grounded in science.” EquiSeq is a leading provider of genetic tests for horses. Since its founding in 2015, the company has been committed to identifying genetic…

Four members of EquiSeq’s Scientific Advisory Board. Left to right: David Nannemann, Paul Szauter, Jesse Young, and Jeremy Edwards. Four members of EquiSeq’s Scientific Advisory Board met on June 2 to get acquainted and to discuss ongoing research projects. Science team members Jeremy Edwards (University of New Mexico), Jesse Young (TriCore Reference Laboratories), David Nannemann (Rosetta Design Group), and Paul Szauter (EquiSeq) attended. Jeremy Edwards will lead the effort to screen whole genome sequence data for potentially damaging variants using an extensive gene list developed by Paul Szauter. David Nannemann will assess the effects of current and future variants on protein structure. Jesse Young will explore the possibility of adding ancestry testing to EquiSeq’s offerings. The meeting marked the first time that some members of the Scientific Advisory Board had met each other. They agreed to continue to meet in person from time to time to supplement email and Zoom meetings. Learn more about EquiSeq’s team on our Team Page.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that a group of twenty countries in Europe have issued a patent on EquiSeq’s DNA test for three genetic variants that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. The following European countries have issued the patent: Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Ireland, Lithuania, Luxemburg, Latvia, Malta, The Netherlands, Portugal, Romania, Sweden, Slovenia and United Kingdom. The patent for EquiSeq’s DNA test has now been issued in 23 countries. The same patent remains pending before patent examiners in Australia and the United States. A second patent is pending in all the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.

Jeremy Edwards, Chair of Department of Chemistry and Chemical Biology at the University of New Mexico, is one of UNM’s most prolific inventors. Dr. Edwards is part of the EquiSeq science team and is an inventor on two of EquiSeq’s patents. In this interview, Dr. Edwards talks about the importance of protecting intellectual property.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that South Africa has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. This is the third patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, the European Union, and the United States. A second patent is pending in the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that New Zealand has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. This is the second patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, South Africa, the European Union, and the United States. A second patent is pending in the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.

ALBUQUERQUE, NEW MEXICO EquiSeq announced today that Canada has issued a patent on EquiSeq’s DNA tests for three genetic variants in horses that predispose to muscle disease. The tests are part of EquiSeq’s current DNA panel. Test results allow horse owners to better manage affected horses, and can be used to improve a breeding program to reduce the incidence of muscle disease. This is the first patent issued to EquiSeq. The same patent remains pending before patent examiners in Australia, New Zealand, South Africa, the European Union, and the United States. A second patent is pending in the same countries. Generatio GmbH performs EquiSeq’s DNA tests for the European Union and United Kingdom, while EquiSeq performs genetic testing for horse owners in the United States and the rest of the world outside of the EU and UK.